Zhang et al. proved that EZH2 inhibitors have a long-term anti-proliferative effect in HCC cells and can be a potential therapeutic target by causing sustained reactivation of de novo silenced genes [20]. This evidence concerns the gene EZH2 and hepatocellular carcinoma.